Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism
Recruitment status was Active, not recruiting
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.|
- The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||January 2007|
|Estimated Study Completion Date:||July 2009|
|Estimated Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.
We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573573
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Study Director:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Chair:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|